RDX013 not checked

Ardelyx

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“RDX013 is an experimental drug that is a potassium secretagogue”In the company’s words, NCT04780841 on ClinicalTrials.gov
Tested for
Hyperkalemia
Main trialPhase 2
“The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels”In the company’s words, NCT04780841 on ClinicalTrials.gov

Other drugs for Hyperkalemia

All 3 drugs for Hyperkalemia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Completed 28 Dec 2021 A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RDX013

Following is part of Solo: you see every change to RDX013 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in